Future role of immunotherapy in HER2+ breast cancer

Veerle Geurts, MD, Netherlands Cancer Institute, Amsterdam, Netherlands, comments on the future use of immunotherapy for the treatment of HER2+ breast cancer, highlighting the need for deeper understanding of the interactions between immune cells and cancer cells. This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.